Board member Murat Kalayoglu to leave Cartesian Therapeutics (RNAC) board March 31, 2026

Rhea-AI Filing Summary

Cartesian Therapeutics, Inc. reported that board member Murat Kalayoglu, M.D., Ph.D. has informed the company he will resign from its Board of Directors, effective March 31, 2026, to pursue other opportunities.

He currently serves as Chairman of the Board’s Science and Technology Committee and as a member of the Nominating and Corporate Governance Committee, and will cease serving on these committees in connection with his resignation. The company states that his decision was not due to any disagreement with the company regarding its operations, policies, or practices and expresses appreciation for his service since 2023.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Terms

Emerging growth company, Nominating and Corporate Governance Committee, Science and Technology Committee, Section 13 or 15(d) of the Securities Exchange Act of 1934

4 terms

Emerging growth company regulatory

"Emerging growth company o o"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Nominating and Corporate Governance Committee financial

"and as a member of the Board’s Nominating and Corporate Governance Committee."

A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.

Science and Technology Committee financial

"served as Chairman of the Board’s Science and Technology Committee"

Section 13 or 15(d) of the Securities Exchange Act of 1934 regulatory

"Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934"

Understanding 8-K Material Events →

0001453687false00014536872026-03-262026-03-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 26, 2026

CARTESIAN THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-37798

26-1622110

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

7495 New Horizon Way, Frederick, MD 21703

(Address of principal executive offices)(Zip Code)

(301) 348-8698

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock (Par Value $0.0001)			RNAC			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 26, 2026, Murat Kalayoglu, M.D., Ph.D., a member of the Board of Directors (the “Board”) of Cartesian Therapeutics, Inc. (the “Company”), notified the Company of his intent to resign from the Board, effective as of March 31, 2026, to pursue other opportunities. Prior to his resignation, Dr. Kalayoglu served as Chairman of the Board’s Science and Technology Committee and as a member of the Board’s Nominating and Corporate Governance Committee. In connection with his resignation from the Board, Dr. Kalayoglu will cease service on such committees. Dr. Kalayoglu’s resignation was not the result of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Dr. Kalayoglu served on the Board since 2023. The Company thanks Dr. Kalayoglu for his advice and leadership as a member of the Board and wishes Dr. Kalayoglu well as he pursues other opportunities.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			CARTESIAN THERAPEUTICS, INC.
Date: March 30, 2026			By:			/s/ Carsten Brunn, Ph.D.
						Carsten Brunn, Ph.D.
						President, Chief Executive Officer and Chairman of the Board

FAQ

What did Cartesian Therapeutics (RNAC) disclose in this 8-K filing?

Cartesian Therapeutics disclosed that board member Murat Kalayoglu, M.D., Ph.D., notified the company of his resignation from the Board of Directors, effective March 31, 2026. He is stepping down to pursue other opportunities, and the company thanked him for his advice and leadership.

When will Murat Kalayoglu’s resignation from Cartesian Therapeutics’ board be effective?

His resignation from the Board of Directors will be effective March 31, 2026. He notified Cartesian Therapeutics of his intent to resign on March 26, 2026, giving several days’ notice before his departure becomes effective and his board and committee service ends.

Did Murat Kalayoglu resign from Cartesian Therapeutics (RNAC) due to a disagreement?

The company states that Murat Kalayoglu’s resignation was not the result of any disagreement with Cartesian Therapeutics regarding its operations, policies, or practices. This indicates the departure is being presented as amicable rather than driven by conflicts over company matters.

What board committees did Murat Kalayoglu serve on at Cartesian Therapeutics?

Before his resignation, Murat Kalayoglu served as Chairman of the Board’s Science and Technology Committee and as a member of the Nominating and Corporate Governance Committee. With his resignation, he will cease serving on both committees at Cartesian Therapeutics.

How long has Murat Kalayoglu served on the Cartesian Therapeutics (RNAC) board?

The filing notes that Murat Kalayoglu has served on the Board of Directors of Cartesian Therapeutics since 2023. His announced resignation effective March 31, 2026, ends a board tenure of several years during which he also held key committee responsibilities.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.3 KB